NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) on behalf of Fulgent stockholders. Our investigation concerns whether Fulgent has violated the federal securities laws and/or engaged in other unlawful […]

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against ADTRAN Holdings, Inc. (“ADTRAN” or the “Company”) (NASDAQ:ADTN) on behalf of ADTRAN stockholders. Our investigation concerns whether ADTRAN has violated the federal securities laws and/or engaged in other unlawful business

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Luna Innovation, Inc. (OTC: LUNA) on behalf of long-term stockholders following a class action complaint that was filed against Luna Innovation on April 1, 2024 with a Class Period from

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Intellia Therapeutics, Inc. (NASDAQ:NTLA) on behalf of long-term stockholders following a class action complaint that was filed against Intellia on February 11, 2025 with a Class Period from July 30,

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share. In addition, Gyre has granted the

VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce it has closed the acquisition to acquire 100% of the issued and outstanding shares of NoBrainer Imaging Centers, Inc. (“NIC”)

BOSTON, May 22, 2025 (GLOBE NEWSWIRE) — CECOCECO, a leading innovator in the lighting and display industry, is excited to announce its participation in the AIA Conference on Architecture & Design 2025, taking place from June 4-7 in Boston. At Booth #1119, CECOCECO will present the latest edition of ArtMorph–an innovative luminous wall panel that

Hidrovias International Finance S.à r.l., a private limited liability company (société à responsabilité limitée) incorporated in the Grand Duchy of Luxembourg, having its registered office at 17, Boulevard F.W. Raiffeisen, L-2411 Luxembourg, Grand Duchy of Luxembourg, and registered with the Luxembourg Register of Commerce and Companies (Registre de commerce et des sociétés, Luxembourg) under number

ROCKVILLE, Md. and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced that new clinical data from two ongoing investigational studies evaluating lisaftoclax in various blood cancers and alrizomadlin in solid tumors will be presented during

As global demographics shift, the aging population becomes a defining force in product innovation. At the 137th China Import and Export Fair (Canton Fair), Chinese companies have been embracing this trend with technology-driven, senior-centric solutions designed to promote safety, independence, and dignity for older adults. One standout exhibitor, Guangzhou SELAQUA Sanitary Ware Co., Ltd. (Aicube